SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP reminded investors of a securities class-action lawsuit against ARS Pharmaceuticals (NASDAQ: SPRY), alleging violations of Sections 10(b) and 20(a) of U.S. securities laws. The notice creates litigation and potential reputational risk for the biotech company, though the provided article excerpt contains no allegations detail, financial damages, deadlines, or company response.